Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ピリミジン化合物
Document Type and Number:
Japanese Patent JP2008546698
Kind Code:
A
Abstract:
This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of formula (I). Each variable in this formula is defined in the specification.

Inventors:
Yen, Ji Feng
Hu, Chen-Kun
Butterfly, min-chen
Tseng, Chen-Zo
Wu, Chen-Fan
Fan, In-Fay
Chen, Shugen
Kin, Chi-Shin, Richard
Application Number:
JP2008517014A
Publication Date:
December 25, 2008
Filing Date:
June 13, 2006
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
Taigen Biotechnology Company, Limited
International Classes:
C07D239/42; A61K31/505; A61K31/506; A61K31/5377; A61K31/55; A61K31/551; A61K31/675; A61P9/10; A61P11/00; A61P11/02; A61P11/06; A61P19/02; A61P21/00; A61P25/16; A61P25/28; A61P27/02; A61P29/00; A61P31/18; A61P35/00; A61P35/02; A61P37/02; A61P37/06; A61P37/08; C07D239/48; C07D239/50; C07D401/04; C07D401/12; C07D401/14; C07D403/04; C07D403/12; C07D405/12; C07D409/12; C07F9/6509
Domestic Patent References:
JP2004300156A2004-10-28
JPH04211040A1992-08-03
JP2001518094A2001-10-09
JP2003519130A2003-06-17
JP2003527303A2003-09-16
JP2006188445A2006-07-20
Foreign References:
WO2004052862A12004-06-24
WO2004074260A12004-09-02
WO2003082855A12003-10-09
WO2004005281A12004-01-15
WO2006090853A12006-08-31
WO2005085212A12005-09-15
WO2006025567A12006-03-09
Other References:
JPN6011069682; Purandare, Ashok V.; Gao, Aiming; Wan, Honghe; Somerville, John; Burke,     Christine; Seachord, Car: 'Identification of chemokine receptor CCR4 antagonist' Bioorganic and Medicinal Chemistry Letters 15(10), 2005, 2669-2672
JPN6011069684; Strekowski, L.; Mokrosz, M.; Mokrosz, J. L.; Strekowska, A.; Allison, S.     A.; Wilson, W. D.: 'Amplification of bleomycin-mediated degradation of DNA by polyamines' Anti-Cancer Drug Design 3(2), 1988, 79-89
Attorney, Agent or Firm:
Hatta International Patent Corporation